Fibrinolytic degradation products in the urine of carcinoma of the prostate patients.
A study of the levels of urinary fibrinolytic degradation products was undertaken in patients with different stages of carcinoma of the prostate trying to detect latent fibrinolysis. No differences between the control group and patients with carcinoma were found. The search for a rapid screening diagnostic test for latent intravascular coagulation should be pursued in order to prevent possible bleeding complications in these patients.